Optimizing NKT cell ligands as vaccine adjuvants

Immunotherapy

Volumn 6, Issue 3, 2014, Pages 309-320

  Carreño, Leandro J ^a,b   Kharkwal, Shalu Sharma ^a   Porcelli, Steven A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

adjuvants; NKT cells; vaccine; galactosylceramide

Indexed keywords

ADJUVANT; ALPHA GALACTOSYLCERAMIDE; ANTIGEN; CELL SURFACE PROTEIN; GLYCOLIPID; IMMUNOMODULATING AGENT; LIGAND; VACCINE; 1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA-GALACTOSYLCERAMIDE; BACTERIAL ANTIGEN; BACTERIAL VACCINE; CANCER VACCINE; CD1D ANTIGEN; CD1D PROTEIN, HUMAN; CYTOKINE; GALACTOSYLCERAMIDE; IMMUNOLOGICAL ADJUVANT; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

CLINICAL OBSERVATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION; NATURAL KILLER T CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; ACTIVE IMMUNOTHERAPY; AGONISTS; ANIMAL; BACTERIAL INFECTIONS; DENDRITIC CELL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; NEOPLASMS; PRIMATE; SECRETION (PROCESS);

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; ANTIGENS, BACTERIAL; ANTIGENS, CD1D; ANTIGENS, NEOPLASM; BACTERIAL INFECTIONS; BACTERIAL VACCINES; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; GALACTOSYLCERAMIDES; GLYCOLIPIDS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ACTIVE; LIGANDS; LYMPHOCYTE ACTIVATION; MICE; NATURAL KILLER T-CELLS; NEOPLASMS; PRIMATES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; VACCINATION;

EID: 84899553729     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.175     Document Type: Review

References (116)

1. Behar SM, Porcelli SA. CD1-restricted T cells in host defense to infectious diseases. Curr. Top. Microbiol. Immunol. 314, 215-250 (2007).
2. Crowe NY, Coquet JM, Berzins SP et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202(9), 1279-1288 (2005).
3. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Ann. Rev. Immunol. 21, 483-513 (2003).
4. Wu L, Van Kaer L. Natural killer T cells and autoimmune disease. Curr. Mol. Med. 9(1), 4-14 (2009).
5. Arase H, Arase N, Saito T. Interferon gamma production by natural killer (NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking. J. Exp. Med. 183(5), 2391-2396 (1996).
6. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 25, 297-336 (2007).
7. Godfrey DI, Macdonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: What's in a name? Nat. Rev. Immunol. 4(3), 231-237 (2004).
8. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195(5), 625-636 (2002).
9. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2(8), 557-568 (2002).
10. Bricard G, Porcelli SA. Antigen presentation by CD1 molecules and the generation of lipid-specific T cell immunity. Cell Mol. Life Sci. 64(14), 1824-1840 (2007).
11. Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 16(4), 583-594 (2002).
12. Behar SM, Podrebarac TA, Roy CJ, Wang CR, Brenner MB. Diverse TCRs recognize murine CD1. J. Immunol. 162(1), 161-167 (1999).
13. Terabe M, Swann J, Ambrosino E et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202(12), 1627-1633 (2005).
14. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199(7), 947-957 (2004).
15. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: Development, specificity, and function. Annu. Rev. Immunol. 15, 535-562 (1997).
16. Brigl M, Brenner MB. CD1: Antigen presentation and T cell function. Annu. Rev. Immunol. 22, 817-890 (2004).
17. Im JS, Kang TJ, Lee SB et al. Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections. Clin. Immunol. 127(2), 214-224 (2008).
18. Sandberg JK, Bhardwaj N, Nixon DF. Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. Eur. J. Immunol. 33(3), 588-596 (2003).
19. Fernandez CS, Jegaskanda S, Godfrey DI, Kent SJ. In-vivo stimulation of macaque natural killer T cells with alphagalactosylceramide. Clin. Exp. Immunol. 173(3), 480-492 (2013).
20. Padte NN, Boente-Carrera M, Andrews CD et al. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS ONE 8(10), e78407 (2013).
21. Wen X, Rao P, Carreno LJ et al. Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells. Proc. Natl Acad. Sci. USA 110(8), 2963-2968 (2013).
22. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4(12), 1230-1237 (2003).
23. Coquet JM, Chakravarti S, Kyparissoudis K et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1-NKT cell population. Proc. Natl Acad. Sci. USA 105(32), 11287-11292 (2008).
24. Goto M, Murakawa M, Kadoshima-Yamaoka K et al. Murine NKT cells produce Th17 cytokine interleukin-22. Cell. Immunol. 254(2), 81-84 (2009).
25. Im JS, Tapinos N, Chae GT et al. Expression of CD1d molecules by human schwann cells and potential interactions with immunoregulatory invariant NK T cells. J. Immunol. 177(8), 5226-5235 (2006).
26. Michel ML, Keller AC, Paget C et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J. Exp. Med. 204(5), 995-1001 (2007).
27. Uldrich AP, Crowe NY, Kyparissoudis K et al. NKT cell stimulation with glycolipid antigen in vivo: Costimulationdependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175(5), 3092-3101 (2005).
28. Stetson DB, Mohrs M, Reinhardt RL et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J. Exp. Med. 198(7), 1069-1076 (2003).
29. Matsuda JL, Gapin L, Fazilleau N, Warren K, Naidenko OV, Kronenberg M. Natural killer T cells reactive to a single glycolipid exhibit a highly diverse T cell receptor beta repertoire and small clone size. Proc. Natl Acad. Sci. USA 98(22), 12636-12641 (2001).
30. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science 268(5212), 863-865 (1995).
31. Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8-T cells. J. Exp. Med. 186(1), 109-120 (1997).
32. Cohen NR, Garg S, Brenner MB. Antigen presentation by CD1 lipids, T cells, and NKT cells in microbial immunity. Adv. Immunol. 102, 1-94 (2009).
33. Matsuda JL, Gapin L, Sidobre S et al. Homeostasis of V alpha 14i NKT cells. Nat. Immunol. 3(10), 966-974 (2002).
34. Sakuishi K, Oki S, Araki M, Porcelli SA, Miyake S, Yamamura T. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J. Immunol. 179(6), 3452-3462 (2007).
35. Godfrey DI, Kronenberg M. Going both ways: Immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114(10), 1379-1388 (2004).
36. Carnaud C, Lee D, Donnars O et al. Cutting edge: Crosstalk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163(9), 4647-4650 (1999).
37. Fujii S, Shimizu K, Hemmi H, Steinman RM. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol. Rev. 220, 183-198 (2007).
38. Kitamura H, Ohta A, Sekimoto M et al. alphagalactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell. Immunol. 199(1), 37-42 (2000).
39. Nishimura T, Kitamura H, Iwakabe K et al. The interface between innate and acquired immunity: Glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int. Immunol. 12(7), 987-994 (2000).
40. Venkataswamy MM, Porcelli SA. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin. Immunol. 22(2), 68-78 (2010).
41. Gumperz JE, Roy C, Makowska A et al. Murine CD1drestricted T cell recognition of cellular lipids. Immunity 12(2), 211-221 (2000).
42. Joyce S, Woods AS, Yewdell JW et al. Natural ligand of mouse CD1d1: Cellular glycosylphosphatidylinositol. Science 279(5356), 1541-1544 (1998).
43. Zhou D, Mattner J, Cantu C, 3rd et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306(5702), 1786-1789 (2004).
44. Christiansen D, Milland J, Mouhtouris E et al. Humans lack iGb3 due to the absence of functional iGb3-synthase: Implications for NKT cell development and transplantation. PLoS Biol. 6(7), e172 (2008).
45. Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Grone HJ. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl Acad. Sci. USA 104(14), 5977-5982 (2007).
46. Li Y, Teneberg S, Thapa P, Bendelac A, Levery SB, Zhou D. Sensitive detection of isoglobo and globo series tetraglycosylceramides in human thymus by ion trap mass spectrometry. Glycobiology 18(2), 158-165 (2008).
47. Speak AO, Salio M, Neville DC et al. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc. Natl Acad. Sci. USA 104(14), 5971-5976 (2007).
48. Sanderson JP, Brennan PJ, Mansour S et al. CD1d protein structure determines species-selective antigenicity of isoglobotrihexosylceramide (iGb3) to invariant NKT cells. Eur. J. Immunol. 43(3), 815-825 (2013).
49. Tahiri F, Li Y, Hawke D et al. Lack of iGb3 and Isoglobo-Series glycosphingolipids in pig organs used for xenotransplantation: Implications for natural killer T-cell biology. J. Carbohydr. Chem. 32(1), 44-67 (2013).
50. Brennan PJ, Tatituri RV, Brigl M et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat. Immunol. 12(12), 1202-1211 (2011).
51. Tatituri RV, Watts GF, Bhowruth V et al. Recognition of microbial and mammalian phospholipid antigens by NKT cells with diverse TCRs. Proc. Natl Acad. Sci. USA 110(5), 1827-1832 (2013).
52. Amprey JL, Im JS, Turco SJ et al. A subset of liver NK T cells is activated during Leishmania donovani infection by CD1dbound lipophosphoglycan. J. Exp. Med. 200(7), 895-904 (2004).
53. Fischer K, Scotet E, Niemeyer M et al. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc. Natl Acad. Sci. USA 101(29), 10685-10690 (2004).
54. Godfrey DI, Rossjohn J. New ways to turn on NKT cells. J. Exp. Med. 208(6), 1121-1125 (2011).
55. Kinjo Y, Tupin E, Wu D et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7(9), 978-986 (2006).
56. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278(5343), 1626-1629 (1997).
57. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7 (10-11), 529-534 (1995).
58. Im JS, Yu KO, Illarionov PA et al. Direct measurement of antigen binding properties of CD1 proteins using fluorescent lipid probes. J. Biol. Chem. 279(1), 299-310 (2004).
59. Sidobre S, Naidenko OV, Sim BC, Gascoigne NR, Garcia KC, Kronenberg M. The V alpha 14 NKT cell TCR exhibits high-Affinity binding to a glycolipid/CD1d complex. J. Immunol. 169(3), 1340-1348 (2002).
60. Im JS, Arora P, Bricard G et al. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 30(6), 888-898 (2009).
61. Arora P, Venkataswamy MM, Baena A et al. A rapid fluorescence-based assay for classification of iNKT cell activating glycolipids. J. Am. Chem. Soc. 133(14), 5198-5201 (2011).
62. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413(6855), 531-534 (2001).
63. Yu KO, Im JS, Molano A et al. Modulation of CD1drestricted NKT cell responses by using N-Acyl variants of alpha-galactosylceramides. Proc. Natl Acad. Sci. USA 102(9), 3383-3388 (2005).
64. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J. Exp. Med. 198(11), 1631-1641 (2003).
65. Tashiro T, Sekine-Kondo E, Shigeura T et al. Induction of Th1-biased cytokine production by alpha-carba-GalCer, a neoglycolipid ligand for NKT cells. Int. Immunol. 22(4), 319-328 (2010).
66. Padte NN, Li X, Tsuji M, Vasan S. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin. Immunol. 140(2), 142-151 (2011).
67. Li X, Fujio M, Imamura M et al. Design of a potent CD1dbinding NKT cell ligand as a vaccine adjuvant. Proc. Natl Acad. Sci. USA 107(29), 13010-13015 (2010).
68. Oki S, Chiba A, Yamamura T, Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J. Clin. Invest. 113(11), 1631-1640 (2004).
69. Mccarthy C, Shepherd D, Fleire S et al. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J. Exp. Med. 204(5), 1131-1144 (2007).
70. Forestier C, Takaki T, Molano A et al. Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. J. Immunol. 178(3), 1415-1425 (2007).
71. Chang YJ, Huang JR, Tsai YC et al. Potent immunemodulating and anticancer effects of NKT cell stimulatory glycolipids. Proc. Natl Acad. Sci. USA 104(25), 10299-10304 (2007).
72. Patel O, Pellicci DG, Uldrich AP et al. Vbeta2 natural killer T cell antigen receptor-mediated recognition of CD1dglycolipid antigen. Proc. Natl Acad. Sci. USA 108(47), 19007-19012 (2011).
73. Carreno LJ, Riquelme EM, Gonzalez PA et al. T-cell antagonism by short half-life pMHC ligands can be mediated by an efficient trapping of T-cell polarization toward the APC. Proc. Natl Acad. Sci. USA 107(1), 210-215 (2010).
74. Gonzalez PA, Carreno LJ, Coombs D et al. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc. Natl Acad. Sci. USA 102(13), 4824-4829 (2005).
75. Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hogquist KA. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat. Immunol. 14(11), 1146-1154 (2013).
76. Kang SJ, Cresswell P. Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat. Immunol. 5(2), 175-181 (2004).
77. Yuan W, Qi X, Tsang P et al. Saposin B is the dominant saposin that facilitates lipid binding to human CD1d molecules. Proc. Natl Acad. Sci. USA 104(13), 5551-5556 (2007).
78. Zhou D, Cantu C, 3rd, Sagiv Y et al. Editing of CD1dbound lipid antigens by endosomal lipid transfer proteins. Science 303(5657), 523-527 (2004).
79. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alphagalactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198(2), 267-279 (2003).
80. Stober D, Jomantaite I, Schirmbeck R, Reimann J. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J. Immunol. 170(5), 2540-2548 (2003).
81. Kitamura H, Iwakabe K, Yahata T et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189(7), 1121-1128 (1999).
82. Venkataswamy MM, Baena A, Goldberg MF et al. Incorporation of NKT cell-Activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J. Immunol. 183(3), 1644-1656 (2009).
83. Lisbonne M, Diem S, De Castro Keller A et al. Cutting edge: Invariant V alpha 14 NKT cells are required for allergeninduced airway inflammation and hyperreactivity in an experimental asthma model. J. Immunol. 171(4), 1637-1641 (2003).
84. Kobrynski LJ, Sousa AO, Nahmias AJ, Lee FK. Cutting edge: Antibody production to pneumococcal polysaccharides requires CD1 molecules and CD8+ T cells. J. Immunol. 174(4), 1787-1790 (2005).
85. Schofield L, Mcconville MJ, Hansen D et al. CD1d-restricted immunoglobulin G formation to GPI-Anchored antigens mediated by NKT cells. Science 283(5399), 225-229 (1999).
86. Singh N, Hong S, Scherer DC et al. Cutting edge: Activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol. 163(5), 2373-2377 (1999).
87. Galli G, Pittoni P, Tonti E et al. Invariant NKT cells sustain specific B cell responses and memory. Proc. Natl Acad. Sci. USA 104(10), 3984-3989 (2007).
88. Devera TS, Shah HB, Lang GA, Lang ML. Glycolipidactivated NKT cells support the induction of persistent plasma cell responses and antibody titers. Eur. J. Immunol. 38(4), 1001-1011 (2008).
89. Galli G, Nuti S, Tavarini S et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J. Exp. Med. 197(8), 1051-1057 (2003).
90. Bai L, Deng S, Reboulet R et al. Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-Term memory to pneumococcal capsular polysaccharides. Proc. Natl Acad. Sci. USA 110(40), 16097-16102 (2013).
91. Lang GA, Devera TS, Lang ML. Requirement for CD1d expression by B cells to stimulate NKT cell-enhanced antibody production. Blood 111(4), 2158-2162 (2008).
92. Gray JD, Horwitz DA. Activated human NK cells can stimulate resting B cells to secrete immunoglobulin. J. Immunol. 154(11), 5656-5664 (1995).
93. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195(5), 617-624 (2002).
94. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY. alpha- Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175(5), 3309-3317 (2005).
95. Kamijuku H, Nagata Y, Jiang X et al. Mechanism of NKT cell activation by intranasal coadministration of alphagalactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol. 1(3), 208-218 (2008).
96. Youn HJ, Ko SY, Lee KA et al. A single intranasal immunization with inactivated influenza virus and alphagalactosylceramide induces long-Term protective immunity without redirecting antigen to the central nervous system. Vaccine 25(28), 5189-5198 (2007).
97. Kopecky-Bromberg SA, Fraser KA, Pica N et al. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 27(28), 3766-3774 (2009).
98. Lee YS, Lee KA, Lee JY et al. An alpha-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine. Vaccine 29(3), 417-425 (2011).
99. Huang Y, Chen A, Li X et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alphagalactosylceramide. Vaccine 26(15), 1807-1816 (2008).
100. Shibolet O, Alper R, Zlotogarov L et al. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int. J. Cancer 106(2), 236-243 (2003).
101. Chung Y, Qin H, Kang CY, Kim S, Kwak LW, Dong C. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood 110(6), 2013-2019 (2007).
102. Kim YJ, Ko HJ, Kim YS et al. alpha-Galactosylceramideloaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity. Int. J. Cancer 122(12), 2774-2783 (2008).
103. Kim D, Hung CF, Wu TC, Park YM. DNA vaccine with alpha-galactosylceramide at prime phase enhances antitumor immunity after boosting with antigen-expressing dendritic cells. Vaccine 28(45), 7297-7305 (2010).
104. Teng MW, Westwood JA, Darcy PK et al. Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res. 67(15), 7495-7504 (2007).
105. Giaccone G, Punt CJ, Ando Y et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8(12), 3702-3709 (2002).
106. Nieda M, Okai M, Tazbirkova A et al. Therapeutic activation of Valpha24+Vbeta11 +NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103(2), 383-389 (2004).
107. Okai M, Nieda M, Tazbirkova A et al. Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide- pulsed dendritic cells. Vox Sang. 83(3), 250-253 (2002).
108. Kunii N, Horiguchi S, Motohashi S et al. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 100(6), 1092-1098 (2009).
109. Richter J, Neparidze N, Zhang L et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 121(3), 423-430 (2013).
110. Veldt BJ, Van Der Vliet HJ, Von Blomberg BM et al. Randomized placebo controlled Phase I/II trial of alphagalactosylceramide for the treatment of chronic hepatitis C. J. Hepatol. 47(3), 356-365 (2007).
111. Woltman AM, Ter Borg MJ, Binda RS et al. Alphagalactosylceramide in chronic hepatitis B infection: Results from a randomized placebo-controlled Phase I/II trial. Antivir. Ther. 14(6), 809-818 (2009).
112. Sullivan BA, Kronenberg M. Activation or anergy: NKT cells are stunned by alpha-galactosylceramide. J. Clin. Invest. 115(9), 2328-2329 (2005).
113. Parekh VV, Wilson MT, Olivares-Villagomez D et al. Glycolipid antigen induces long-Term natural killer T cell anergy in mice. J. Clin. Invest. 115(9), 2572-2583 (2005).
114. Thapa P, Zhang G, Xia C et al. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 27(25-26), 3484-3488 (2009).
115. Leung B, Harris HW. NKT cells in sepsis. Clin. Dev. Immunol. 2010, doi:10.1155/2010/414650 (2010).
116. Stirnemann K, Romero JF, Baldi L et al. Sustained activation and tumor targeting of NKT cells using a CD1d-Anti-HER2-scFv fusion protein induce antitumor effects in mice. J. Clin. Invest. 118(3), 994-1005 (2008).